31.7 C
New York
Sunday, June 14, 2026

Tag: note

Completion of the Sale of the Share of Saare Kala Tootmine OÜ

AS PRFoods (registry code 11560713) hereby notifies that its subsidiary Saaremere Kala AS (registry code  11310040, hereinafter "Seller") has completed previously announced transaction (as disclosed in a stock exchange announcement published by AS PRFoods on 23 April 2026 (https://view.news.eu.nasdaq.com/view?id=1436682&lang=en), whereby 100% shareholding in Saare Kala Tootmine OÜ (registry code 10377013, hereinafter "SKT") was sold and claims arising from shareholder loans and an inventory loan provided to SKT were transferred to the Latvian company Brīvais Vilnis A/S (Latvian registry code: 40003056186, hereinafter "Buyer"). The general meeting of shareholders of AS PRFoods approved the transaction by their relevant resolution published on 18 May 2026 (https://view.news.eu.nasdaq.com/view?id=1442522&lang=en). In accordance with the terms of the transaction, the vendor note agreement concluded between the Seller and the Buyer and setting out the terms of the payment by the Buyer to the Seller of the amount equal to the outstanding purchase price for the share of SKT and of the transfer price for the inventory loans has entered into force upon completion of the transaction.

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026. 

High Tide to Open Two New Canna Cabana Locations in Welland and Calgary

CALGARY, AB, June 10, 2026 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward...

Power Metallic Mines Announces Closing of Brokered LIFE Offering for Gross Proceeds of C$28.2 Million and Welcomes Eric Sprott as a New Shareholder

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, June 10, 2026 /CNW/ - Power...

FRONTIER LITHIUM AND HANWHA SIGN MEMORANDUM OF UNDERSTANDING TO EXPLORE STRATEGIC COOPERATION ACROSS THE LITHIUM VALUE CHAIN

GREATER SUDBURY, ON, June 10, 2026 /CNW/ - Frontier Lithium Inc. ("Frontier") announces that it has entered into a non-binding memorandum of understanding (the...

Solidion Technology Withdraws Previously Filed Registration Statement

The withdrawal does not reflect any change in the Company's business outlook, operating strategy, or confidence in the value of its assetsDALLAS, June 10,...

Motul Returns as Official Lubricant Partner for Great Wall Motor Factory Racing

SINGAPORE, June 10, 2026 /PRNewswire/ -- Motul is proud to be the official lubricant partner of Great Wall Motor (GWM) Factory Racing for the...

D3PUBLISHER Announces EARTH DEFENSE FORCE 5 and EARTH DEFENSE FORCE 6 for Nintendo Switch 2

Worldwide launch of EARTH DEFENSE FORCE 5 scheduled for October 8, 2026; EARTH DEFENSE FORCE 6 planned for release this winterTOKYO, June 10, 2026...

ING rolls out global subscription banking model

ING rolls out global subscription banking model

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNote